InDex Pharmaceuticals provides an update on company’s future
26 February, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) announces that, in light of today’s separate press release, with the announcement that the development of cobitolimod is discontinued, the company is evaluating other alternatives to maximize shareholder value. Alternatives such as merger and reverse merger are weighed against company liquidation. InDex Pharmaceuticals will not proceed with development of any of its other compounds.A step-wise approach has been adopted to narrow down the number of options. Company liquidation is considered in parallel at
CONCLUDE CDE and EPLASS CDE meet SOC 2 and C5 security requirementsMunich, 26 February 2024 – Thinkproject, the leading European SaaS provider of solutions for the construction industry, has received an official SOC 2 attestation for its SaaS solutions CONCLUDE CDE and EPLASS CDE. The U.S. SOC 2 security standard (System and Organization Controls 2), which has been defined by the American Institute of Certified Public Accountants (AICPA), is primarily aimed at security in cloud computing, unlike standards such as ISO/IEC 27001. The standard also aims to create maximum information security
